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Introduction
Hypoxia defi nes a pathological condition where 
oxygen is delivered to the tissue in insuffi cient 
quantities, which is the result of impaired oxygen 
transport mechanism. Hypoxic conditions may 
have the features of the pathological process, e.g. 
during the development of uncontrolled proliferative 
lesions [1, 2]. Regardless of the stage of the cancer, 
tumor hypoxia is considered to be unfavorable 
prognostic factor [3]. Hypoxic cells exhibit greater 
resistance to all therapeutic modes [4] and provide 
higher probability of metastasis and recurrence [5]. 
Therefore, the determination of the level and spatial 
distribution of hypoxia in tumor cells is an important 
diagnostic problem. 
In recent years, the molecular imaging methods, 
in particular positron emission tomography (PET), 
proved the effectiveness in the diagnosis of hypoxic 
conditions. 
As a radiopharmaceutical for the diagnosis 
of hypoxia, a complex of radioactive copper-64 
(t1/2 = 12.7 h) with a neutral lipophilic molecule 
ATSM (diacetyl-bis(N4-methylthiosemicarbazone)) 
was successfully applied [6]. 64Cu(II)-ATSM was 
reduced in hypoxic in vivo conditions and converted 
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chromatography (HPLC) and the radiochemical purity of radiotracer was higher than 99%. Proposed [18F]FMISO 
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into an anion [Cu(I) ATSM]−, which was trapped 
inside the cells, particularly in poorly vascularized 
areas in the state of cell cycle arrest. 64Cu-ATSM was 
an excellent marker for live cells in a hypoxic state 
but did not accumulate in the areas of necrosis, thus 
the amount of captured 64Cu-ATSM by tumor cells 
was inversely proportional to the chance of survival 
and lifetime without metastasis or recurrence [7]. 
The most widely used marker for imaging hypoxic 
conditions is [18F]fl uoromisonidazole ([18F]FMISO) 
labeled with fl uorine-18 (t1/2 = 110 min), routinely 
and worldwide manufactured isotope for neuro- and 
oncological diagnostics. As other molecules contain-
ing 2-nitroimidazole moiety is reduced in hypoxic 
cells, whereby it is used as an indicator of the oxy-
gen concentration in tumor cells [8]. Imaging with 
[18F]FMISO takes 20–30 min (whole body scan) and 
is performed 2–4 hours after administration. Because 
the [18F]FMISO is not captured by the areas covered 
by necrosis, it requires the presence of living cells in 
hypoxic pO2 level below 10 mmHg [9]. [18F]FMISO 
increased its clinical signifi cance when noninvasive 
assessment of hypoxia has been applied for detect-
ing the differences between various types of tumors 
and delineation of hypoxic areas in radiation therapy 
planning. 
In preclinical research, [18F]FMISO examination 
started to be a tool for phenotypes characterization 
[10], monitoring of anticancer treatments [11], re-
sponse evaluation [12], and molecular backgrounds 
of spontaneous tumors [13]. 
This paper describes an application of 
[18F]FMISO for the preclinical studies on small 
animals. The scope of this study was to synthesize 
[18F]FMISO in a number of consecutive runs using 
fl uorine from target fl ushing after the commercial 
manufacturing of fl uorodeoxyglucose ([18F]FDG) and 
to prove the quality of manufactured radiopharma-
ceuticals, as a proof of concept in studies on hypoxia 
in Lewis lung carcinoma (LLC) in mouse models. 
Materials and methods 
[18F]FMISO synthesis
[18F]FMISO was synthesized by nucleophilic 
fl uorination of NITTP (1-(2-nitro-1-imidazolyl)-
-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-
-propanediol) with acidic hydrolysis. Cyclotron GE 
PETtrace 840 with high-yield niobium target (Gen-
eral Electric, Uppsala, Sweden) was the source of 
anionic fl uorine. Standard produced activity in the 
18O(p,n)18F reaction with a 16.5-MeV proton beam 
at 40–45 A was 4.0 ± 0.2 Ci (140.6–155.4 GBq) 
after 120 min of irradiation, and this was used for 
commercial 18FDG synthesis. 
For animal studies, residual activity (4.0–6.0 GBq 
of fl uorine in 2.2 ml of H2O) from fl ushing the target 
after commercial 18FDG synthesis was transferred to 
the Synthra RNplus unit (Synthra, Germany), where 
the [18F]FMISO synthesis and purifi cation were per-
formed (Fig. 1). Precursor NITTP in 5 mg portions 
and Kryptofi x in acetonitrile were obtained from 
ABX (Radeberg, Germany); other reagents such as 
potassium carbonate p.a., anhydrous acetonitrile 
(high-performance liquid chromatography (HPLC) 
grade), ethanol (HPLC grade), and hydrochloric 
acid p.a. were obtained from Avantor Chemicals 
(Gliwice, Poland). 
Identifi cation and quality control 
Identity of manufactured [18F]FMISO was con-
fi rmed by comparison of retention time to the cer-
tifi ed reference standard (CRS) of main compound 
(ABX, Radeberg, Germany). 
Radiochemical purity was performed with 
chromatography system Shimadzu AD20 with 
UV-Vis (ultraviolet-visible) and radiometric detector 
(GabiStar, Raytest, Germany). Twenty microliters 
Fig. 1. Control panel and scheme of Synthra RNPlus module. (A) 18F trapping and separation from target; (B) 18F labeling 
of precursor; (C) purifi cation of intermediate product; (D) acidic hydrolysis; (E) HPLC purifi cation and fi nal formulation. 
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of sample was injected via manual multiport valve. 
The separation was done on Phenomenex Gemini 
C18 column (150 mm × 4.0 mm i.d., 10 m), with 
95:5 H2O:EtOH as a mobile phase and 1 mL/min 
fl ow rate. 
Other identifi cation tests, half-life measurements, 
pH, residual solvents, and radionuclidic purity were 
performed as described earlier for [18F]FDG [14]. 
Animals and tumor model 
LLC cells were grown at 37°C in a humidifi ed atmo-
sphere of 5% CO2/95% air in RPMI 1640 containing 
10% heat-inactivated fetal bovine serum plus peni-
cillin-streptomycin under sterile tissue culture condi-
tions. C57BL/6JOlaHsd, N = 10 female mice of 8–10 
weeks of age and about 20 g of each were originally 
obtained from the animal breeding facility at the Fac-
ulty of Biochemistry, Biophysics and Biotechnology of 
the Jagiellonian University (Cracow, Poland). All the 
experimental procedures were approved by the First 
Local Ethic Committee of the Jagiellonian University 
(Permission Nos. 107/2013 and 91/2014). Mice were 
kept under constant conditions of 12/12 light cycle, 
humidity of 60%, and temperature of about 23°C. 
Standard laboratory diet with free access to drink-
ing water were given in community cages. For each 
mouse, 0.5 × 106 LLC cells, suspended in 100 L of 
PBS, was injected intradermally into the right hind 
limb. The tumors became visible in 4–6 days after im-
plantation. When their size (greatest diameter) were 
about 5 mm, mice were transported in cages specially 
prepared for this purpose to Biological and Chemical 
Research Centre of the University of Warsaw. Positron 
emission tomography-computed tomography (PET/
CT) measurements were performed after minimum 
24 hours of acclimation after travel. 
PET/CT measurements 
Experiments were performed on Albira PET/
SPECT/CT Preclinical Imaging System (Bruker, 
Germany). Before measurements, mice were anes-
thetized with 2% isofl urane (Aerrane, Baxter Polska 
Sp. z o.o., Poland) in oxygen delivered through a 
nose cone and place on the heating pad. Thin can-
nula connected with a pressure equalizing (PE) tube 
(PE 50) of 15 cm long fi lled with saline was placed 
in tail vein. Prepared mice were placed in the supine 
position in the imager with the use of the animal 
bed, and 10–15 MBq [18F]FMISO was administered 
i.v. through tail vein cannula. Isofl urane anesthesia 
were maintained through entire radiopharmaceuti-
cal uptake and image acquisition. Respiration was 
monitored with pressure pad connected to differ-
ential pressure transducers for low-range pressure 
monitoring (Biopac MP150 Acquisition System) 
during entire PET/CT examination and regulated 
by changing isofl urane concentration. PET scans 
were performed 120 min after injection. Emission 
data were collected for 1, 5, and 10 min. Spatial 
resolution of PET measurements was 1.1 mm. The 
scan parameters were set as follow: tube voltage was 
45 kVp, tube current was 400 A, and number of 
projections was 400. Minimal resolution of CT was 
90 m. The PET and CT images were fused using 
a PMOD software. Because the mouse remains in 
the same position on the bed for both PET and CT 
acquisitions, the software module can use the po-
sitional information to fuse and coregister the PET 
and CT data. 
Results and discussion
Synthesis
[18F]FMISO was synthetized by direct nucleophilic 
[18F]fl uorination of NITTP (Fig. 2) in commercially 
available module Synthra RNPlus. As a source of 
fl uorine, the water after fi rst fl ushing of the irradi-
ated target has been used. In standard conditions, 
activities in range 4.0–6.0 GBq were obtained and 
directed to the synthesis unit. 
First, the solution was passed through an ion-
-exchange column (Chromafi x 731876 PS-HCO3−), 
which trapped 18F anions. Then, fl uoride was eluted 
to the reaction vessel with a mixture of potassium 
carbonate and Kryptofi x 2.2.2. Water was removed 
by azeotropic distillation with anhydrous acetonitrile 
and 18F reacted with 5 mg of NITTP. Reaction mix-
ture was purifi ed on C18 SPE column (Chromafi x 
731805 (C18EC)) and further fl uorinated precur-
sor was eluted with ethanol to the second reactor, 
where 1.5 mL of 1 M hydrochloric acid was added 
for hydrolysis (5 min, 100°C). 
After acidic hydrolysis, the solution was puri-
fi ed with built-in HPLC on C18-RP (Phenomenex 
Gemini C18 250 mm × 10 mm × 7 m). This method 
of separation was confi rmed as the most effective 
purifi cation method [15]. To receive high specifi c 
activity, the modifi cation of synthesis module was 
done to enable the collection of the fraction with 
highest activity of fi nal product. The 1-mL portion 
of the most concentrated product at the output form 
HPLC column was cut-off by valve V27 and directly 
delivered with helium stream to the fi nal product 
vial, after passing through the 0.22-m sterile fi lter. 
Finally, it was formulated with saline (0.9% w/v) 
and dispensed in manual module DDS-A (Tema 
Sinergie, Italy). 
Radiochemical yield was 35.1 ± 1.2% (not cor-
rected); total synthesis time including activity and 
fi nal product transfer was 50–52 min, which is 
Fig. 2. Synthesis of [18F]FMISO.
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comparable to recently published papers [15, 16], 
taking into consideration yield dependency on initial 
precursor mass [17]. 
The labeling reaction was followed with pre-
parative HPLC, ensuring good separation of fi nal 
product from impurities and the radiochemical 
purity >99%. On the basis of the starting activity of 
4.0–6.0 GBq, 1.2–1.7 GBq of product with specifi c 
activity of 200–250 MBq/mL was obtained, which 
was suffi cient for the injection of several animals in 
standard imaging mode. 
Quality control 
18F was identifi ed by recording the principal -peak at 
511.5 ± 0.3 keV and determining the half-life (108.8 
± 0.3 min). The presence of any peaks with an en-
ergy different from 511 keV was checked and, except 
signals coming from Pb-X-rays (range 70–80 keV), 
none was found. That confi rmed a better than 99.9% 
radionuclidic purity. Then the sample was left for 
24 h to decay and again impurities were tested with 
no signifi cant peaks, except residual activity of 18F. 
[18F]FMISO was identifi ed, comparing the reten-
tion times of standards, observed in the reference 
chromatogram with retention time of the principal 
signal in the radiochromatogram (Fig. 3). Recorded 
retention times were 4.42 min for the standard and 
4.65 min for the principal peak in radiochromatogram. 
Radiochemical purity was determined by HPLC 
with radiometric detection, where the peak of 
[18F]FMISO was observed at 4.65 min, with no other 
signals recorded (Fig. 3b). The average content of 
[18F]FMISO was higher than 99%. Six consecutive 
runs were analyzed in triplicate each. Osmolality of 
formulated product was 310 mOsm/kg; pH ranged 
6.5–7.4. 
Imaging
The synthesized and HPLC-purifi ed [18F]FMISO 
was used for PET imaging in a mouse model carry-
ing LLC tumor. For comparison, the same mouse 
was also imaged with [18F]FDG. The results show 
a difference in the distribution of [18F]FDG and 
[18F]FMISO in the body (Fig. 4). 
The physiological uptake of glucose is located in 
the heart and bladder; in the case of [18F]FMISO, 
tracer is accumulated in the intestine and bladder. 
It confi rms other studies in which [18F]FMISO had 
physiological affi nity to the gastrointestinal tract 
[11]. In the stomach and intestine, high absorption 
was observed 30 min after the injection, whereas in 
the kidney, uptake increased 30 min after injection 
and remained in bladder at a high level to 120 min. 
The visible difference in the structure of imaged 
cancer with [18F]FDG and [18F]FMISO is observed 
– for the fi rst tracer, tumor area is spherical and 
[18F]FMISO is accumulated in two separated sites. 
While [18F]FMISO was accumulated in relatively 
hypoxic areas of the tumor, 18[F]FDG was pref-
erentially taken up by metabolically active tumor 
regions. The reason for the differences in structure 
of imaged tumor depends on the uptake mechanism 
of the marker [18], where the uptake of [18F]FDG 
in the tumor is caused by increased glucose metabo-
lism and [18F]FMISO is the result of the presence of 
hypoxic areas of the tumor tissue. 
Fig. 3. Radiochemical purity and identity for [18F]FMISO. 
(a) Radiochromatogram compared with (b) UV-Vis 
(254 nm) reference. 
Fig. 4. In vivo imaging of a mouse carrying LLC tumor 
with [18F]FDG (a) and [18F]FMISO (b) with detailed 
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Conclusions 
Synthesis of [18F]FMISO using 5 mg of precur-
sor NITTP offered reliable manufacturing of good 
yield and high-purity radiopharmaceutical. The 
modifi cations to the synthesis unit allowed to receive 
suffi cient activity to perform PET experiments in 
animal subjects. Produced [18F]FMISO was used 
as a reliable tool in studies on hypoxia in LLC in 
mouse models. 
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